Abstract | OBJECTIVES: METHODS: RESULTS: Current evidence to support a rifampin combination therapy as a treatment for non-mycobacterial infections was largely based on in vitro/in vivo studies and non-comparable retrospective case series. Additionally, controlled clinical trials that directly compared outcomes resulting from rifampin treatment versus treatment without rifampin were limited. CONCLUSIONS:
Rifampin combination therapy appears promising for the treatment of non-mycobacterial infections. However, further definitive clinical trials are necessary to validate its use because the risk of adverse drug-drug interactions and of the emergence of rifampin resistance during treatment may outweigh the potential benefits.
|
Authors | Chun-Yuan Lee, Chung-Hao Huang, Po-Liang Lu, Wen-Chien Ko, Yen-Hsu Chen, Po-Ren Hsueh |
Journal | The Journal of infection
(J Infect)
Vol. 75
Issue 5
Pg. 395-408
(11 2017)
ISSN: 1532-2742 [Electronic] England |
PMID | 28870736
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2017 The British Infection Association. Published by Elsevier Ltd. All rights reserved. |
Chemical References |
- Anti-Bacterial Agents
- Rifampin
|
Topics |
- Anti-Bacterial Agents
(therapeutic use)
- Bacterial Infections
(drug therapy)
- Humans
- Mycobacterium Infections
- Rifampin
(therapeutic use)
|